Psychedelic Institute of Mental Health & Family Therapy
Psychedelic Institute of Mental Health & Family Therapy
Telehealth Ketamine Therapists
⌘K
Contact
Psychedelic Institute of Mental Health & Family Therapy
depression

Spotlight: Nearly half of depression diagnoses could be considered treatment-resistant (ScienceDaily, 2025)

Mixed methods study found hopelessness among patients struggling with condition after trying multiple antidepressants
Michael DeMarco, PhD

by Michael DeMarco, PhD

Spotlight: Nearly half of depression diagnoses could be considered treatment-resistant (ScienceDaily, 2025)
Nearly half of depression diagnoses could be considered treatment-resistant (ScienceDaily, 2025)
Nearly half of depression diagnoses could be considered treatment-resistant
Almost half of patients diagnosed with depression classify as being ‘treatment-resistant’ as new research suggests that many don’t respond to multiple antidepressant options.
ScienceDaily

Examining the needs, outcomes and current treatment pathways of 2461 people with treatment-resistant depression: mixed-methods study | The British Journal of Psychiatry | Cambridge Core
Examining the needs, outcomes and current treatment pathways of 2461 people with treatment-resistant depression: mixed-methods study
Cambridge CoreKiranpreet Gill

More like this

Spotlight: "Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition (Oughli, et al, 2023)

"This pilot study suggests that repeated IV ketamine infusions are well-tolerated and are associated with improvement in depression and EF in older adults with TRD."

Spotlight: MDMA + Psychotherapy as a treatment for major depressive disorder: proof of principle study (Kvam, et al, 2025)

"There were no adverse events of special interest, and no unexpected or serious adverse events. The study met the primary objectives of safety and feasibility, and provided indications of efficacy for MDMA-AT for MDD. Further studies with a randomised design are required to confirm these findings."

Spotlight: Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial

"Patients treated with ketamine demonstrated superior cognitive functioning compared with ECT following a 3-week treatment, no differences between treatments observed. Findings support short-term superiority of ketamine on cognitive functioning and the long-term cognitive safety of both treatments."

Preservative-free formulation of ketamine, NRX-100, Granted FDA Fast-Track Designation for Suicidal Ideation in Patients with Depression, including Bipolar Depression

"Approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – designed to help address national crisis."
Spotlight: Long-term benefits of single-dose psilocybin in depressed patients with cancer (Agrawal, et al, 2025)

Spotlight: Long-term benefits of single-dose psilocybin in depressed patients with cancer (Agrawal, et al, 2025)

"These findings demonstrate robust antidepressive activity from a single 25 mg dose of psilocybin combined with psychotherapy and suggest a potentially paradigm-changing alternative to traditional antidepressants requiring further study."

Spotlight: UK Medical Cannabis Registry: A clinical outcomes analysis for insomnia (Aggarwal, et al, 2025)

"The study demonstrated improvements in subjective sleep quality and other captured PROMs in insomnia patients treated with cannabis-based medicinal products."
Mastodon Mastodon